Search Result

Results for "

Cystic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CFTR (42) ADC Linker (1) Antibiotic (1) Apoptosis (2) Autophagy (12) Bacterial (9) Biochemical Assay Reagents (2) Cathepsin (1) CDK (1) Chloride Channel (1) COX (2) E1/E2/E3 Enzyme (1) Elastase (2) Endogenous Metabolite (1) ERK (1) Glucosylceramide Synthase (GCS) (2) GLUT (1) GnRH Receptor (1) GSK-3 (1) GSNOR (1) Isotope-Labeled Compounds (2) JNK (1) LPL Receptor (1) Mitochondrial Metabolism (3) P-glycoprotein (3) Parasite (5) Phosphodiesterase (PDE) (1) Potassium Channel (3) PROTACs (1) Protein Arginine Deiminase (1) Sodium Channel (5) Trk Receptor (1) TRP Channel (2)
By Research Areas:	Cancer (9) Endocrinology (9) Infection (14) Inflammation/Immunology (36) Metabolic Disease (7) Neurological Disease (5)
Click Chemistry:	Alkynes (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: CFTR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111111

Galicaftor 1 Publications Verification ABBV-2222; GLPG-2222	CFTR	Inflammation/Immunology
Galicaftor (ABBV-2222; GLPG-2222) is a potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Galicaftor can be used for cystic fibrosis research .

HY-112267A

(R)-Olacaftor (R)-VX-440	CFTR	Others
(R)-Olacaftor ((R)-VX-440) is a Cystic fibrosis transmembrane conductance regulator (CFTR) modulator. (R)-Olacaftor has good potential for the study of cystic fibrosis (CF) .

HY-147315

CFTR corrector 9	CFTR	Others
CFTR corrector 9 (compound 42) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. CFTR corrector 9 can be used for researching cystic fibrosis (CF) and other CFTR associated disorders .

HY-109187A

Posenacaftor sodium 1 Publications Verification PTI-801 sodium	CFTR	Inflammation/Immunology
Posenacaftor (PTI-801) sodium is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor sodium is used for the research of cystic fibrosis (CF) .

HY-133013

GLPG-3221	CFTR	Inflammation/Immunology
GLPG-3221 is a potent, orally active corrector of CFTR (cystic fibrosis transmembrane conductance regulator), with an EC₅₀ of 105 nM. GLPG-3221 can be uesd for the treatment of cystic fibrosis .

HY-135279

CFTR corrector 4	CFTR	Inflammation/Immunology
CFTR corrector 4 (Compound 13), an active (R,R)-form enantiomer, is a highly potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector. CFTR corrector 4 can increase CFTR levels at the cell surface and have the potential for treatment of cystic fibrosis .

HY-111680

Nesolicaftor 2 Publications Verification PTI-428	CFTR Autophagy	Endocrinology
Nesolicaftor (PTI-428) is a specific cystic fibrosis transmembrane conductance regulator (CFTR) amplifier .

HY-161085

BI 1265162

Sodium Channel Metabolic Disease

BI 1265162 is a potent inhibitor of endothelial sodium channel (ENaC) that plays an important role in cystic fibrosis research .
HY-145603A

(R)-Vanzacaftor

(R)-VX-121
CFTR Others

(R)-Vanzacaftor ((R)-VX-121) is a regulator of cystic fibrosis transmembrane conduction regulator (CFTR) .

BI 1265162	Sodium Channel	Metabolic Disease
BI 1265162 is a potent inhibitor of endothelial sodium channel (ENaC) that plays an important role in cystic fibrosis research .

(R)-Vanzacaftor (R)-VX-121	CFTR	Others
(R)-Vanzacaftor ((R)-VX-121) is a regulator of cystic fibrosis transmembrane conduction regulator (CFTR) .

HY-109187

Posenacaftor PTI-801	CFTR	Inflammation/Immunology
Posenacaftor (PTI-801) is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor is used for the research of cystic fibrosis (CF) .

HY-109152

Navocaftor

GLPG 3067; ABBV-3067
CFTR Others

Navocaftor (GLPG 3067), as a cystic fibrosis transmembrane regulator (CFTR), is a protein modulator (US 20200377491 Al, example 1) .

Navocaftor GLPG 3067; ABBV-3067	CFTR	Others
Navocaftor (GLPG 3067), as a cystic fibrosis transmembrane regulator (CFTR), is a protein modulator (US 20200377491 Al, example 1) .

HY-111772

Elexacaftor Maximum Cited Publications 21 Publications Verification VX-445	CFTR Autophagy	Inflammation/Immunology
Elexacaftor (VX-445, Compound 1) is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR). Elexacaftor (VX-445, Compound 1) facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface .

HY-109187B

(R)-Posenacaftor sodium (R)-PTI-801 sodium	CFTR	Inflammation/Immunology
(R)-Posenacaftor (R)-PTI-801) sodium is the R enantiomer of Posenacaftor. Posenacaftor is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor is used for the research of cystic fibrosis (CF) .

HY-147249

CFTR corrector 8

CFTR Inflammation/Immunology

CFTR corrector 8 is a potent CFTR modulator. CFTR can be used in the research of cystic fibrosis .

CFTR corrector 8	CFTR	Inflammation/Immunology
CFTR corrector 8 is a potent CFTR modulator. CFTR can be used in the research of cystic fibrosis .

HY-116535C

D-threo-PPMP	Glucosylceramide Synthase (GCS)	Neurological Disease
D-threo-PPMP is a potent inhibitor of glucosylceramide (GlcCer) synthase. D-threo-PPMP can block karyokinesis and reduce cyst production .

HY-116535

D-threo-PPMP hydrochloride	Glucosylceramide Synthase (GCS)	Neurological Disease
D-threo-PPMP hydrochloride is a potent inhibitor of glucosylceramide (GlcCer) synthase. D-threo-PPMP hydrochloride can block karyokinesis and reduce cyst production .

HY-15448A

(Rac)-Tezacaftor (Rac)-VX-661	CFTR	Inflammation/Immunology
(Rac)-Tezacaftor ((Rac)-VX-661) is a racemate of Tezacaftor (HY-15448). Tezacaftor is a F508del CFTR corrector. (Rac)-Tezacaftor can be used for the research of cystic fibrosis .

HY-126394B

Bamocaftor potassium VX-659 potassium	CFTR	Endocrinology
Bamocaftor potassium is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor potassium can be used combine with Tezacaftor (HY-15448) and Ivacaftor (HY-13017) in cystic fibrosis research .

HY-126394

Bamocaftor VX-659	CFTR	Endocrinology
Bamocaftor (VX-659) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor can be used combine with Tezacaftor (HY-15448) and Ivacaftor (HY-13017) in cystic fibrosis research .

HY-136939

CFTR corrector 6	CFTR	Metabolic Disease Inflammation/Immunology
CFTR corrector 6 is a potent potentiator of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). CFTR corrector 6 has the potential for cystic fibrosis (CF) and other CFTR associated disorders research .

HY-128361

SLC26A3-IN-3

GLUT Inflammation/Immunology

SLC26A3-IN-3 (compound 4az) is a SLC26A3 inhibitor (IC₅₀: 40 nM). SLC26A3-IN-3 can be used for research of constipation, cystic fibrosis .

SLC26A3-IN-3	GLUT	Inflammation/Immunology
SLC26A3-IN-3 (compound 4az) is a SLC26A3 inhibitor (IC₅₀: 40 nM). SLC26A3-IN-3 can be used for research of constipation, cystic fibrosis .

HY-P5924

L-K6L9	Bacterial	Infection
L-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. L-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance .

HY-P5924A

D-K6L9	Bacterial	Infection
D-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. D-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance .

HY-143344

NJH-2-056	PROTACs CFTR	Inflammation/Immunology
NJH-2-056 is a deubiquitinase-targeting chimera (DUBTAC) linking the OTUB1 recruiter EN523 to the CFTR chaperone lumacaftor. NJH-2-056 can be used for cystic fibrosis research .

HY-109027

Cavosonstat N91115	GSNOR CFTR	Inflammation/Immunology
Cavosonstat (N91115) is an orally active S-nitrosoglutathione reductase (GSNOR) inhibitor. Cavosonstat is a CFTR stabilizer, and can be used for cystic fibrosis research .

HY-13017S

Ivacaftor-d9 VX-770-d₉	CFTR	Cancer
Ivacaftor-d₉ is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research[1].

HY-108858

Dornase alfa rhDNase	Others	Others
Dornase alfa (rhDNase) is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. Dornase alfa plays an important role in cystic fibrosis .

HY-106302

Duramycin Moli1901; Lancovutide	Bacterial	Infection Inflammation/Immunology
Duramycin (Moli1901) is a lantibiotic derived from Streptomyces cinnamoneuma. Duramycin also is a antimicrobial peptide. Duramycin can be used for the research of cystic fibrosis (CF) .

HY-I0501

2'-Aminoacetophenone	Bacterial	Inflammation/Immunology
2'-Aminoacetophenone is an aromatic compound containing a ketone substituted by one alkyl group, and a phenyl group. 2'-Aminoacetophenone can be used as a breath biomarker for the detection of Ps. Aeruginosa infections in the cystic fibrosis lung .

HY-109177

Icenticaftor QBW251	CFTR	Inflammation/Immunology
Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC₅₀s of 79 nM and 497 nM for F508del and G551D CFTR, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research .

HY-150090

SRI-41315	CFTR	Inflammation/Immunology
SRI-41315 induces a prolonged pause at stop codons and suppresses PTCs (premature termination codons) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR (cystic fibrosis transmembrane conductance regulator) expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity .

HY-N2687

5-n-Tricosylresorcinol	Others	Others
5-n-Tricosylresorcinolthe is the first cyst lipid. 5-n-Tricosylresorcinolthe has metahydroxyl group which allows it to self-associate forming a staggered-chain conformation in which the polar head groups have heaxagonal symmetry .

HY-145603

Vanzacaftor

VX-121
CFTR Inflammation/Immunology

Vanzacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR) for researching cystic fibrosis.

Vanzacaftor VX-121	CFTR	Inflammation/Immunology
Vanzacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR) for researching cystic fibrosis.

HY-148806

Zatonacaftor	CFTR	Inflammation/Immunology
Zatonacaftor is a modulator of cystic fibrosis transmembrane regulator (CFTR) protein. Zatonacaftor can be used for research of cystic fibrosis .

HY-128358

MR-L2	Phosphodiesterase (PDE)	Neurological Disease
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC₅₀ of 1.2 µM .

HY-139786

Cofirasersen ION-827359	Sodium Channel	Others
Cofirasersen is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene.

HY-139786A

Cofirasersen sodium ION-827359 sodium	Sodium Channel	Others
Cofirasersen sodium is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene.

HY-112363

Aloisine A RP107	CDK GSK-3 ERK JNK CFTR	Inflammation/Immunology Cancer
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC₅₀s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC₅₀=0.5 μM) and GSK-3β (IC₅₀=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research .

HY-103370

Talniflumate BA 7602-06	Chloride Channel	Inflammation/Immunology
Talniflumate (BA 7602-06) is the proagent of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase . Talniflumate is an orally active Ca ²⁺-activated Cl ^- channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome .

HY-15206

Glibenclamide 15+ Cited Publications Glyburide	Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glibenclamide (Glyburide) is an orally active ATP-sensitive K ⁺ channel (K_ATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of K_ATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

HY-13017A

Ivacaftor benzenesulfonate VX-770 benzenesulfonate	CFTR Autophagy	Endocrinology
Ivacaftor benzenesulfonate is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.

HY-19970

KM11060 2 Publications Verification	CFTR Autophagy	Endocrinology
KM11060 is a corrector of the F508 deletion (F508del)-cystic fibrosis transmembrane conductance regulator (CFTR) trafficking defect. KM11060 can be used for the research of F508del-CFTR processing defect and development of cystic fibrosis research .

HY-13017B

Ivacaftor hydrate

VX-770 hydrate
CFTR Autophagy Endocrinology

Ivacaftor hydrate (VX-770 hydrate) is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.
HY-P0053

Fertirelin

GnRH Receptor Others

Fertirelin is a GnRH and LH-RH analogue; it also becomes the treatment choice for reversing cow follicular cysts.

Ivacaftor hydrate VX-770 hydrate	CFTR Autophagy	Endocrinology
Ivacaftor hydrate (VX-770 hydrate) is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.

Fertirelin	GnRH Receptor	Others
Fertirelin is a GnRH and LH-RH analogue; it also becomes the treatment choice for reversing cow follicular cysts.

HY-125381

CFTR corrector 2 1 Publications Verification	CFTR Autophagy	Inflammation/Immunology Cancer
CFTR corrector 2 is a cystic fibrosis transmembrane conductance corrector (CFTR), extracted from patent US20140274933 .

HY-112267

Olacaftor

VX-440
CFTR Autophagy Inflammation/Immunology

Olacaftor (VX-440) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator extracted from patent US9782408.
HY-151673

Poc-Cystamine

ADC Linker Others

Poc-Cystamine (compound PPA-cyst) is a click chemistry reagent, a cystamine building block derived from a propynyl group .

Olacaftor VX-440	CFTR Autophagy	Inflammation/Immunology
Olacaftor (VX-440) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator extracted from patent US9782408.

HY-108464A

Phenamil methanesulfonate	Sodium Channel TRP Channel	Metabolic Disease Inflammation/Immunology
Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible epithelial sodium channel (ENaC) blocker with an IC₅₀ of 400 nM . Phenamil methanesulfonate is also a competive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca ²⁺ transport with an IC₅₀ of 140 nM in a Ca ²⁺ uptake assay . Phenamil methanesulfonate is an intriguing small molecule to promote bone repair by strongly activating BMP signaling pathway . Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease .

HY-P0051

Lecirelin
Lecirelin, a synthetic gonadotropin-releasing hormone (GnRH) analogue, acts as a GnRH agonist. Lecirelin is widely used for the research of bovine ovarian follicular cysts .

HY-N2057

Steviol

Steviol is a major metabolite of the sweetening compound stevioside. Steviol slows renal cyst growth by reducing AQP2 expression and promoting AQP2 degradation .

Cat. No.	Product Name	Target	Research Area

HY-P0053

Fertirelin

GnRH Receptor Others

Fertirelin is a GnRH and LH-RH analogue; it also becomes the treatment choice for reversing cow follicular cysts.

HY-P3293A

Lonodelestat TFA POL6014 TFA	Elastase	Inflammation/Immunology
Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor of *human neutrophil elastase (hNE). Lonodelestat TFA has the potential for the research of cystic* fibrosis (CF) .**

HY-P5924

L-K6L9	Bacterial	Infection
L-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. L-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance .

HY-P5924A

D-K6L9	Bacterial	Infection
D-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. D-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance .

HY-P3293

Lonodelestat POL6014	Elastase	Inflammation/Immunology
Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat (POL6014) has the potential for the research of cystic fibrosis (CF) .

HY-P2697

PA22-2 free acid Cys-Laminin A chain 2091-2108	Peptides	Others
PA22-2 (free acid) (Cys-Laminin A chain 2091-2108) is a peptide that supports neurite outgrowth and stimulates neuronal-like process formation. PA22-2 (free acid) can be used to culture human adenoid cystic carcinoma cells, and in the preparation of peptide-functionalized supported phospholipid bilayers .

HY-P5509

C5aR1 antagonist peptide	Peptides	Others
C5aR1 antagonist peptide is a biological active peptide. (This linear peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions to inhibit C5a binding and function at human and rat C5a receptors. C5a is crucial to triggering cellular immune responses and its overexpression is involved in arthritis, Alzheimer’s disease, cystic fibrosis, systemic lupus erythematosus, and other immunoinflammatory diseases.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-106302

Duramycin Moli1901; Lancovutide	Microorganisms Classification of Application Fields Source classification Inflammation/Immunology Disease Research Fields	Bacterial
Duramycin (Moli1901) is a lantibiotic derived from Streptomyces cinnamoneuma. Duramycin also is a antimicrobial peptide. Duramycin can be used for the research of cystic fibrosis (CF) .

HY-I0501

2'-Aminoacetophenone	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields Inflammation/Immunology	Bacterial
2'-Aminoacetophenone is an aromatic compound containing a ketone substituted by one alkyl group, and a phenyl group. 2'-Aminoacetophenone can be used as a breath biomarker for the detection of Ps. Aeruginosa infections in the cystic fibrosis lung .

HY-N2687

5-n-Tricosylresorcinol	Microorganisms Classification of Application Fields Source classification Other Diseases Phenols Polyphenols Disease Research Fields	Others
5-n-Tricosylresorcinolthe is the first cyst lipid. 5-n-Tricosylresorcinolthe has metahydroxyl group which allows it to self-associate forming a staggered-chain conformation in which the polar head groups have heaxagonal symmetry .

HY-137680

GP4G Diguanoside tetraphosphate	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
GP4G (Diguanoside tetraphosphate) is a symmetrical bis-diphospho nucleoside that can be isolated from the cysts of Artemia salina. GP4G is an epithelial cell and hair growth regulator .

Species:	Human (3)
Tag:	His (3)
Source:	Sf9 insect cells (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P70531

	S100A8 Protein, Human (C-His) Protein S100-A8; S100A8; Calgranulin-A; Cystic fibrosis antigen; Leukocyte L1 complex light chain; MRP-8	Human	E. coli
	S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (C-His) is the recombinant human-derived S100A8 protein, expressed by E. coli , with C-6*His labeled tag. The total length of S100A8 Protein, Human (C-His) is 93 a.a., with molecular weight of ~13.0 kDa.

HY-P70531A

	S100A8 Protein, Human (N-His) Protein S100-A8; S100A8; Calgranulin-A; Cystic fibrosis antigen; Leukocyte L1 complex light chain; MRP-8	Human	E. coli
	S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (N-His) is the recombinant human-derived S100A8 protein, expressed by E. coli , with N-6*His labeled tag. The total length of S100A8 Protein, Human (N-His) is 93 a.a., with molecular weight of ~12 kDa.

HY-P76586

	S100A8 Protein, Human (sf9, His) Protein S100-A8; S100A8; Calgranulin-A; Cystic fibrosis antigen; Leukocyte L1 complex light chain; MRP-8	Human	Sf9 insect cells
	S100A8 consists of calcium and zinc bound S100A8, which plays a critical regulatory role in inflammation and immune responses. As calprotectin, it contributes to leukocyte function, regulates the cytoskeleton, and activates intracellular NADPH oxidase. S100A8 Protein, Human (sf9, His) is the recombinant human-derived S100A8 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of S100A8 Protein, Human (sf9, His) is 93 a.a., with molecular weight of ~14.6 kDa.

Cat. No.	Product Name	Chemical Structure

HY-13017S

Ivacaftor-d9
Ivacaftor-d₉ is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research[1].

HY-15206S1

Glyburide-d3

Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-78131S3

Ibuprofen-13C6

Ibuprofen- ¹³C₆ ((±)-Ibuprofen- ¹³C₆) is a ¹³C labeled Ibuprofen (HY-78131). Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers .

HY-13017S1

Ivacaftor-d19
Ivacaftor-d₉ is a potent CFTR modulator and exhibits an EC₅₀ value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research .

HY-15206S

Glyburide-d11

Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks